Adenoviral gene therapy with catalase suppresses experimental optic neuritis

Archives of Ophthalmology

Volumn 117, Issue 11, 1999, Pages 1533-1539

  Guy, John ^a,b   Qi, Xiaoping ^a   Wang, Hui ^a   Hauswirth, William W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Department of Clinical and Health Psychology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; HYDROGEN PEROXIDE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HISTOPATHOLOGY; MOUSE; NONHUMAN; OPTIC NERVE DISEASE; PRIORITY JOURNAL;

EID: 0032725982     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.117.11.1533     Document Type: Article

References (45)

1. Honegger CG, Krenger W, Langemann H. Measurement of free radical scavengers in the spinal cord of rats with experimental allergic encephalomyelitis. Neurosci Lett. 1989;98:327-332.
2. Guy JR, Ellis EA, Hope GM, Rao NA. Antioxidant enzymes reduce loss of blood-brain barrier integrity in experimental allergic encephalomyelitis. Arch Ophthalmol. 1989;107:1359-1363.
3. Guy JR, Ellis EA, Hope GM, Rao NA. Antioxidant enzyme suppression of demyelination in experimental optic neuritis. Curr Eye Res. 1989;8:467-477.
4. Bowern N, Ramshaw IA, Clark IA, Doherty PC. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med. 1984; 160:1532-1543.
5. Guy J, Ellis EA, Hope GM, Rao NA. Influence of antioxidant enzymes in reduction of optic disc edema in experimental optic neuritis. J Free Radio Biol Med. 1986;2:349-357.
6. Ruuls SR, Bauer J, Sontrop K, Huitinga I, Hart BA, Dijkstra CO. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol. 1995;56:207-217.
7. Brett R, Rumsby MG. Evidence of free radical damage in the central nervous system of guinea pigs at the prolonged acute and early relapse stages of chronic relapsing experimental allergic encephalomyelitis. Neurochem Int. 1993;23:35-44.
8. Abuchowski A, McCoy JR, Palczuk NC, Van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem. 1977;252:3582-3586.
9. Guy J, McGorray S, Fitzsimmons J, et al. Reversals of blood-brain barrier disruption by catalase: a serial magnetic resonance imaging study of experimental optic neuritis. Invest Ophthalmol Vis Sci. 1994;35:3456-3465.
10. 2 and BBB disruption in experimental optic neuritis. Invest Ophthalmol Vis Sci. 1994;35:1114-1123.
11. Guy J, Qi X, Hauswirth WW. Adeno-associated viral-mediated calalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc Natt Acad Sci U S A. 1998;95:13847-13852.
12. Erzurum SC, Lemarchand P, Rosenfeld MA, Yoo J-H, Crystal RG. Protection of human endothelial cells from oxidant injury by adenovirus-mediated transfer of the human catalase cDNA. Nucleic Acids Res. 1993;21:1607-1612.
13. Raine CS. Experimental allergic encephalomyelitis and experimental allergic neuritis. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology. Vol 3. Rev ser. Amsterdam, the Netherlands: Elsevier Science Publishers; 1985:429-466.
14. Rao NA. Chronic experimental allergic optic neuritis. Invest Ophthalmol Vis Sci. 1981;20:159-172.
15. Paterson PY, Day ED. Current perspectives of neuroimmunologic disease: multiple sclerosis and experimental allergic encephalomyelitis. Am J Pathol. 1982; 52:251-263.
16. Raine CS. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol. 1997;77:135-152.
17. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis: the Optic Neuritis Study Group. N Engl J Med. 1992;326:581-588.
18. Guy J, Fitzsimmons J, Ellis EA, Beck B, Mancuso A. Intraorbital optic nerve and experimental optic neuritis: correlation of fat suppression magnetic resonance imaging and electron microscopy. Ophthalmology. 1992;99:720-725.
19. Guy J, Fitzsimmons J, Ellis EA, Mancuso A. Gadolinium-DTPA enhanced magnetic resonance imaging in experimental optic neuritis. Ophthalmology. 1990; 97:601-607.
20. Flannery JG, Zolotukhin S, Vaquero Ml, LaVail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A. 1997;94:6916-6921.
21. Bennett J, Wilson J, Sun D, Forbes B, Maguire A. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci. 1994;35: 2535-2542.
22. Li T, Adamian M, Roof DJ, et al. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. Invest Ophthalmol Vis Sci. 1994;35:2543-2549.
23. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol. 1996;70:4646-4654.
24. Mashhour B, Couton D, Perricaudet M, Briand P. In vivo adenovirus-mediated gene transfer into ocular tissues. Gene Ther 1994;1:122-126.
25. Bennett J, Tanabe T, Sun D, et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat Med. 1996;2:649-654.
26. Ali FIR, Reichel MB, Thrasher AJ, et al. Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet. 1996;5:591-594.
27. Akli S, Caillaud C, Vigne E, et al. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet. 1993;3:224-228.
28. Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Rier PJ. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 1997;4:16-24.
29. Weihl C, Macdonald RL, Stoodley M, Luders J, Lin G. Gene therapy for cerebrovascular disease. Neurosurgery. 1999;44:239-252.
30. Cayouette M, Gravel C. Adenovirus-mediated gene transfer to retinal ganglion cells. Invest Ophthalmol Vis Sci. 1996;37:2022-2028.
31. Steinman L. The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease. Adv Immunol. 1991;49: 357-379.
32. Daniel PM, Lam DKC, Pratt OE. Changes in the effectiveness of the blood-brain and blood-spinal cord barriers in experimental allergic encephalomyelitis. J Neurol Sci. 1981;52:211-219.
33. Claudio L, Kress Y, Factor JR, Norton WT, Brosnan CF. Increased vesicular transport and decreased mitochondrial content in blood-brain barrier endothelial cells during experimental autoimmune encephalomyelitis. Am J Pathol. 1989;135: 1157-1168.
34. Lossinsky AS, Badmajew V, Robson JA, Moretz RC, Wisniewski HM. Sites of egress of inflammatory cells and horseradish peroxidase transport across the blood-brain barrier in a murine model of chronic relapsing experimental allergic encephalomyelitis. Acta Neuropathol. 1989;78:359-371.
35. Kim YS, Kim SU. Oligodendroglial cell death induced by oxygen radicals and its protection by catalase. J Neurosci Res. 1991;29:100-106.
36. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70: 8098-8108.
37. Hoffman LM, Maquire AM, Bennett J. Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. Invest Ophthalmol Vis Sci. 1997;38:2224-2233.
38. Haddad IY, Sorscher EJ, Garver RI Jr, Hong J, Tzeng E, Matalon S. Modulation of adenovirus-mediated gene transfer by nitric oxide. Am J Respir Cell Mol Biol. 1997;16:501-509.
39. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 1994;8:148-154.
40. Mulligan R. The basic science of gene therapy. Science. 1993;260:926-932.
41. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A. 1996;93:14082-14087.
42. Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science. 1992;258:1491-1494.
43. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993;259:1321-1324.
44. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987;37:1097-1102.
45. Karussis DM, Lehmann D, Slavin S, et al. Treatment of chronic relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A. 1993;90:6400-6404.